Pfizer’s Covid-19 pill gets U.S. FDA clearance
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Subscribe To Our Newsletter & Stay Updated